Key result
Dedicated transcatheter AR devices link to ~55% lower 30-day mortality trend vs. off-label valves.
Why the study?
Pure native aortic regurgitation poses unique technical challenges for TAVI, and the comparative performance of dedicated versus off-label transcatheter devices via transfemoral access remained incompletely defined.
Do dedicated transcatheter aortic regurgitation devices reduce 30-day mortality and improve procedural outcomes compared with off-label transcatheter devices in adults with pure native aortic regurgitation undergoing transfemoral TAVI?
Meta-Analysis (n=2,956)
Yes
Do dedicated transcatheter aortic regurgitation devices reduce 30-day mortality and improve procedural outcomes compared with off-label transcatheter devices in adults with pure native aortic regurgitation undergoing transfemoral TAVI?
In contemporary transfemoral TAVI for pure native aortic regurgitation, dedicated transcatheter devices demonstrate superior procedural success, lower residual regurgitation, reduced valve embolisation, fewer reinterventions, and a trend toward lower 30-day mortality compared with off-label devices.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“In this issue of AsiaIntervention, Hon and colleagues share a contemporary meta-analysis on TAVI for pure native AR which corroborates these findings and confirms that dedicated transfemoral devices outperform off-label devices for both clinical and valve performance endpoints. One can argue whether more clinical and randomised controlled data are required to offer this safe and effective treatment to patients with native pure AR at elevated operative risk.”
Dedicated devices may improve procedural success in PNAR TAVI; leaves open mortality benefit and requires randomized confirmation.
Background: Pure native aortic regurgitation (PNAR) poses unique technical challenges for transcatheter aortic valve implantation (TAVI), including annular dilatation and absent calcification for anchoring. Whilst dedicated aortic regurgitation (AR) devices have been developed, their comparative performance against off-label devices specifically via transfemoral access - the contemporary standard approach - remains incompletely defined. Aims: We aimed to compare the outcomes of dedicated versus off-label transcatheter devices for PNAR via transfemoral access in contemporary practice. Methods: We systematically searched PubMed (MEDLINE) and Cochrane CENTRAL (January 2020-November 2025) for studies reporting transfemoral TAVI outcomes in PNAR. The primary outcome was 30-day mortality. Random-effects meta-analysis with meta-regression was performed. Results: Twenty-four studies (2,956 patients) were included comprising 25 cohorts: 4 cohorts (537 patients) evaluated dedicated devices, and 21 cohorts (2,419 patients) assessed off-label devices. Overall, 30-day mortality was 3.3% (95% confidence interval [CI]: 2.3-4.8%). Dedicated devices showed a trend towards lower mortality (1.9% vs 4.1%, odds ratio [OR] 0.45, 95% CI: 0.20-1.00; p=0.051; risk ratio 0.40, 95% CI: 0.19-0.83). Dedicated devices achieved higher device success (95.8% vs 85.7%, OR 3.64; p=0.012), lower rates of residual AR >=moderate (0.6% vs 6.2%, OR 0.11; p=0.048), reduced valve embolisation (2.0% vs 7.3%, OR 0.26; p=0.048), and fewer reinterventions (2.0% vs 7.9%, OR 0.22; p=0.010). Permanent pacemaker implantation (20.8%), stroke (2.6%), and major bleeding (3.0%) were similar between groups. Conclusions: In contemporary transfemoral TAVI for PNAR, dedicated devices demonstrated superior procedural outcomes compared with off-label devices. These findings support the preferential use of dedicated devices in this population, though randomised trials are needed to establish definite treatment recommendations.
No takes yet. Share an insight, caveat, or question.
Hon et al. (2026) conducted a meta-analysis in Pure native aortic regurgitation (n=2,956). Dedicated transcatheter aortic regurgitation devices (JenaValve Trilogy, Hanchor Valve) vs. Off-label transcatheter aortic valve devices designed for aortic stenosis was evaluated on 30-day (or in-hospital) all-cause mortality (OR 0.45, 95% CI 0.20-1.00, p=0.051). Dedicated transcatheter devices showed a trend toward lower 30-day mortality (1.9% vs 4.1%, OR 0.45, p=0.051) and higher device success (95.8% vs 85.7%, p=0.012) than off-label devices in PNAR.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: